Participating studies
| Source . | Category . | Study . | Group . | Population group . | Total no. . | % Male . | Age, mean (SD), y . | Fibrinogen mean (SD), g/L . | Fibrinogen method . |
|---|---|---|---|---|---|---|---|---|---|
| TOPMed | Freeze 6 WGS | Amish Research Program | EUR | 558 | 48.0 | 56.3 (14.2) | 3.2 (0.8) | Clauss | |
| Atherosclerosis Risk in Communities (ARIC) | AFR | 664 | 40.5 | 54.2 (6.0) | 3.3 (0.8) | Clauss | |||
| EUR | 5 963 | 45.7 | 54.0 (5.7) | 3.0 (0.6) | |||||
| Coronary Artery Risk Development in Young Adults Study (CARDIA) | AFR | 542 | 39.5 | 26.9 (4.2) | 2.3 (0.5) | Clauss | |||
| EUR | 874 | 45.7 | 28.3 (3.4) | 2.1 (0.5) | |||||
| NA | 131 | 52.7 | 27.0 (3.9) | 2.3 (0.6) | |||||
| Cleveland Family Study (CFS) | AFR | 366 | 43.4 | 40.2 (18.4) | 3.2 (0.9) | Clauss | |||
| EUR | 258 | 47.7 | 45.9 (19.1) | 3.3 (0.7) | |||||
| Cardiovascular Health Study (CHS) | AFR | 497 | 39.4 | 72.4 (5.2) | 3.4 (0.7) | Clauss | |||
| EUR | 2 247 | 44.4 | 72.5 (5.3) | 3.2 (0.7) | |||||
| COPDGene Study | AFR | 188 | 51.6 | 54.3 (7.0) | 5.0 (1.1) | Clauss | |||
| EUR | 1 191 | 48.7 | 62.0 (9.1) | 5.1 (1.2) | |||||
| Framingham Heart Study (FHS) | EUR | 3 535 | 46.2 | 49.2 (11.9) | 3.2 (0.6) | Clauss | |||
| Genetic Study of Atherosclerosis Risk (GeneSTAR) | AFR | 767 | 36.4 | 41.0 (10.9) | 3.8 (1.1) | Clauss | |||
| EUR | 945 | 44.2 | 42.7 (12.3) | 3.6 (1.1) | |||||
| Genetic Epidemiology Network of Arteriopathy (GENOA) | AFR | 703 | 26.6 | 61.0 (10.4) | 3.8 (1.0) | Clauss | |||
| Jackson Heart Study (JHS) | AFR | 2 926 | 38.0 | 54.9 (12.9) | 4.2 (0.9) | Clauss | |||
| Multi-Ethnic Study of Atherosclerosis (MESA) | AFR | 1 082 | 47.2 | 60.8 (9.6) | 3.6 (0.8) | Clauss | |||
| ASN | 1 828 | 49.1 | 61.5 (9.8) | 3.3 (0.7) | |||||
| EUR | 1 014 | 48.6 | 60.2 (9.8) | 3.6 (0.7) | |||||
| HIS | 601 | 50.2 | 61.2 (10.1) | 3.3 (0.6) | |||||
| San Antonio Family Study (SAFS) | HIS | 370 | 35.9 | 41.0 (15.8) | 3.0 (0.7) | Clauss | |||
| NA | 22 | 45.5 | 43.0 (21.6) | 3.2 (1.0) | |||||
| Women’s Health Initiative (WHI) | AFR | 740 | 0.0 | 63.0 (7.0) | 3.2 (0.7) | Clauss | |||
| AI/AN | 35 | 0.0 | 64.0 (7.7) | 3.1 (0.7) | |||||
| ASN | 140 | 0.0 | 66.2 (7.4) | 2.9 (0.6) | |||||
| EUR | 4 213 | 0.0 | 67.2 (6.9) | 3.0 (0.7) | |||||
| HIS | 174 | 0.0 | 62.5 (6.2) | 3.1 (0.7) | |||||
| NA | 20 | 0.0 | 68.0 (7.3) | 3.2 (0.9) | |||||
| No WGS, TOPMed Imputation | ARIC | AFR | 2 170 | 36.4 | 53.2 (5.7) | 3.2 (0.7) | See above | ||
| EUR | 3 790 | 48.6 | 54.6 (5.7) | 3.0 (0.6) | |||||
| CHS | EUR | 1 508 | 38.9 | 72.3 (5.4) | 3.2 (0.6) | See above | |||
| FHS | EUR | 1 565 | 44.5 | 49.5 (11.9) | 3.2 (0.7) | See above | |||
| WHI | GARNET | EUR | 442 | 0.0 | 64.7 (7.5) | 3.2 (0.9) | See above | ||
| ONCO | EUR | 312 | 0.0 | 66.9 (5.8) | 3.1 (0.9) | ||||
| HIPFX | EUR | 133 | 0.0 | 70.5 (4.9) | 3.3 (1.0) | ||||
| SHARE | AFR | 496 | 0.0 | 62.1 (7.3) | 3.5 (0.9) | ||||
| HIS | 357 | 0.0 | 60.1 (6.8) | 3.2 (0.7) | |||||
| CHARGE | TOPMed Imputation | Airwave Health Monitoring Study (Airwave) | EUR | 13 405 | 65.8 | 40.4 (9.0) | 3.8 (1.0) | Clauss | |
| Caerphilly Prospective study (CaPs) | EUR | 1 159 | 100.0 | 56.8 (4.5) | 4.0 (0.8) | Clauss and HN | |||
| CHRIS | EUR | 9 012 | 43.9 | 44.2 (15.4) | 2.8 (0.6) | Clauss | |||
| CROATIA | Korcula | EUR | 798 | 35.4 | 56.3 (14.0) | 4.6 (1.5) | Clauss | ||
| Split | EUR | 953 | 38.9 | 50.3 (14.0) | 4.1 (1.6) | Clauss | |||
| Vis | EUR | 924 | 42.5 | 56.1 (15.6) | 3.6 (0.8) | Clauss | |||
| European Prospective Investigation in Cancer (EPIC) Norfolk Study (EPIC-Norfolk) | EUR | 17 473 | 47.0 | 59.2 (9.2) | 2.9 (1.0) | Clauss | |||
| FHS_omni | AFR | 142 | 37.3 | 53.5 (9.4) | 3.4 (0.7) | Clauss | |||
| HIS | 168 | 36.3 | 49.1 (8.0) | 3.3 (0.6) | |||||
| Genetic Analysis of Idiopathic Thrombophilia (GAIT2) | EUR | 896 | 49.4 | 39.7 (21.4) | 3.5 (0.8) | Clauss | |||
| Helsinki Birth Cohort Study (HBCS) | EUR | 1 321 | 40.6 | 61.4 (2.9) | 3.3 (1.0) | Clauss | |||
| Lothian Birth Cohort 1921 (LBC1921) | EUR | 486 | 42.4 | 76.1 (0.6) | 3.6 (0.9) | Clauss | |||
| Lothian Birth Cohort 1936 (LBC1936) | EUR | 988 | 50.8 | 69.6 (0.8) | 3.3 (0.6) | Clauss | |||
| Ludwigshafen Risk and Cardiovascular Health (LURIC) | EUR | 2 731 | 70.0 | 62.7 (10.6) | 4.0 (1.1) | Clauss | |||
| Marseille Thrombosis Association (MARTHA) | EUR | 985 | 29.0 | 45.4 (14.9) | 3.4 (0.7) | Clauss | |||
| Netherlands Epidemiology of Obesity (NEO) | EUR | 5 303 | 46.8 | 56.0 (6.0) | 3.0 (0.6) | Clauss | |||
| Netherlands Twin Registry (NTR) | EUR | 7 650 | 38.5 | 44.9 (14.6) | 2.8 (0.7) | Clauss | |||
| Precocious Coronary Artery Disease Study (PROCARDIS) | Cases | EUR | 4 196 | 73.0 | 62.2 (7.0) | 4.2 (1.0) | Clauss and IN | ||
| Controls | EUR | 2 224 | 76.2 | 55.1 (8.3) | 3.5 (0.9) | ||||
| Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) | EUR | 4 951 | 48.1 | 75.3 (3.3) | 3.6 (0.7) | Clauss | |||
| RETROVE | Cases | EUR | 398 | 49.2 | 61.8 (18.6) | 3.8 (0.9) | Clauss | ||
| Controls | EUR | 398 | 48.7 | 47.1 (18.2) | 3.4 (0.7) | ||||
| SardiNIA | EUR | 5 931 | 35.9 | 43.6 (17.6) | 3.3 (0.7) | Clauss | |||
| Study of Health in Pomerania (SHIP) | SHIP-START | EUR | 3 571 | 47.5 | 47.5 (15.6) | 3.0 (0.7) | Clauss | ||
| SHIP-TREND-B1 | EUR | 909 | 42.9 | 49.1 (13.4) | 3.0 (0.7) | Clauss | |||
| SHIP-TREND-B2 | EUR | 1 505 | 49.0 | 49.5 (15.0) | 3.0 (0.8) | Clauss | |||
| TWINSUK | EUR | 2 037 | 4.7 | 49.1 (12.6) | 3.0 (0.8) | Clauss | |||
| Viking Health Study-Shetland (VIKING) | EUR | 2 086 | 40.1 | 49.9 (15.2) | 3.5 (0.8) | Clauss | |||
| Women’s Genome Health Study (WGHS) | EUR | 22 962 | 0.0 | 54.2 (7.1) | 3.6 (0.8) | ITA | |||
| HRC Imputation | GOYA | EUR | 1 431 | 100.0 | 45.6 (7.9) | 3.1 (0.8) | FPA | ||
| Inter99 | EUR | 649 | 61.8 | 49.5 (6.4) | 2.1 (1.5) | UI | |||
| Rotterdam Study (RS) | RS1 | EUR | 2 252 | 36.5 | 70.5 (8.9) | 2.8 (0.7) | Clauss | ||
| RS2 | EUR | 673 | 45.5 | 64.8 (8.0) | 3.9 (0.9) | ||||
| Source . | Category . | Study . | Group . | Population group . | Total no. . | % Male . | Age, mean (SD), y . | Fibrinogen mean (SD), g/L . | Fibrinogen method . |
|---|---|---|---|---|---|---|---|---|---|
| TOPMed | Freeze 6 WGS | Amish Research Program | EUR | 558 | 48.0 | 56.3 (14.2) | 3.2 (0.8) | Clauss | |
| Atherosclerosis Risk in Communities (ARIC) | AFR | 664 | 40.5 | 54.2 (6.0) | 3.3 (0.8) | Clauss | |||
| EUR | 5 963 | 45.7 | 54.0 (5.7) | 3.0 (0.6) | |||||
| Coronary Artery Risk Development in Young Adults Study (CARDIA) | AFR | 542 | 39.5 | 26.9 (4.2) | 2.3 (0.5) | Clauss | |||
| EUR | 874 | 45.7 | 28.3 (3.4) | 2.1 (0.5) | |||||
| NA | 131 | 52.7 | 27.0 (3.9) | 2.3 (0.6) | |||||
| Cleveland Family Study (CFS) | AFR | 366 | 43.4 | 40.2 (18.4) | 3.2 (0.9) | Clauss | |||
| EUR | 258 | 47.7 | 45.9 (19.1) | 3.3 (0.7) | |||||
| Cardiovascular Health Study (CHS) | AFR | 497 | 39.4 | 72.4 (5.2) | 3.4 (0.7) | Clauss | |||
| EUR | 2 247 | 44.4 | 72.5 (5.3) | 3.2 (0.7) | |||||
| COPDGene Study | AFR | 188 | 51.6 | 54.3 (7.0) | 5.0 (1.1) | Clauss | |||
| EUR | 1 191 | 48.7 | 62.0 (9.1) | 5.1 (1.2) | |||||
| Framingham Heart Study (FHS) | EUR | 3 535 | 46.2 | 49.2 (11.9) | 3.2 (0.6) | Clauss | |||
| Genetic Study of Atherosclerosis Risk (GeneSTAR) | AFR | 767 | 36.4 | 41.0 (10.9) | 3.8 (1.1) | Clauss | |||
| EUR | 945 | 44.2 | 42.7 (12.3) | 3.6 (1.1) | |||||
| Genetic Epidemiology Network of Arteriopathy (GENOA) | AFR | 703 | 26.6 | 61.0 (10.4) | 3.8 (1.0) | Clauss | |||
| Jackson Heart Study (JHS) | AFR | 2 926 | 38.0 | 54.9 (12.9) | 4.2 (0.9) | Clauss | |||
| Multi-Ethnic Study of Atherosclerosis (MESA) | AFR | 1 082 | 47.2 | 60.8 (9.6) | 3.6 (0.8) | Clauss | |||
| ASN | 1 828 | 49.1 | 61.5 (9.8) | 3.3 (0.7) | |||||
| EUR | 1 014 | 48.6 | 60.2 (9.8) | 3.6 (0.7) | |||||
| HIS | 601 | 50.2 | 61.2 (10.1) | 3.3 (0.6) | |||||
| San Antonio Family Study (SAFS) | HIS | 370 | 35.9 | 41.0 (15.8) | 3.0 (0.7) | Clauss | |||
| NA | 22 | 45.5 | 43.0 (21.6) | 3.2 (1.0) | |||||
| Women’s Health Initiative (WHI) | AFR | 740 | 0.0 | 63.0 (7.0) | 3.2 (0.7) | Clauss | |||
| AI/AN | 35 | 0.0 | 64.0 (7.7) | 3.1 (0.7) | |||||
| ASN | 140 | 0.0 | 66.2 (7.4) | 2.9 (0.6) | |||||
| EUR | 4 213 | 0.0 | 67.2 (6.9) | 3.0 (0.7) | |||||
| HIS | 174 | 0.0 | 62.5 (6.2) | 3.1 (0.7) | |||||
| NA | 20 | 0.0 | 68.0 (7.3) | 3.2 (0.9) | |||||
| No WGS, TOPMed Imputation | ARIC | AFR | 2 170 | 36.4 | 53.2 (5.7) | 3.2 (0.7) | See above | ||
| EUR | 3 790 | 48.6 | 54.6 (5.7) | 3.0 (0.6) | |||||
| CHS | EUR | 1 508 | 38.9 | 72.3 (5.4) | 3.2 (0.6) | See above | |||
| FHS | EUR | 1 565 | 44.5 | 49.5 (11.9) | 3.2 (0.7) | See above | |||
| WHI | GARNET | EUR | 442 | 0.0 | 64.7 (7.5) | 3.2 (0.9) | See above | ||
| ONCO | EUR | 312 | 0.0 | 66.9 (5.8) | 3.1 (0.9) | ||||
| HIPFX | EUR | 133 | 0.0 | 70.5 (4.9) | 3.3 (1.0) | ||||
| SHARE | AFR | 496 | 0.0 | 62.1 (7.3) | 3.5 (0.9) | ||||
| HIS | 357 | 0.0 | 60.1 (6.8) | 3.2 (0.7) | |||||
| CHARGE | TOPMed Imputation | Airwave Health Monitoring Study (Airwave) | EUR | 13 405 | 65.8 | 40.4 (9.0) | 3.8 (1.0) | Clauss | |
| Caerphilly Prospective study (CaPs) | EUR | 1 159 | 100.0 | 56.8 (4.5) | 4.0 (0.8) | Clauss and HN | |||
| CHRIS | EUR | 9 012 | 43.9 | 44.2 (15.4) | 2.8 (0.6) | Clauss | |||
| CROATIA | Korcula | EUR | 798 | 35.4 | 56.3 (14.0) | 4.6 (1.5) | Clauss | ||
| Split | EUR | 953 | 38.9 | 50.3 (14.0) | 4.1 (1.6) | Clauss | |||
| Vis | EUR | 924 | 42.5 | 56.1 (15.6) | 3.6 (0.8) | Clauss | |||
| European Prospective Investigation in Cancer (EPIC) Norfolk Study (EPIC-Norfolk) | EUR | 17 473 | 47.0 | 59.2 (9.2) | 2.9 (1.0) | Clauss | |||
| FHS_omni | AFR | 142 | 37.3 | 53.5 (9.4) | 3.4 (0.7) | Clauss | |||
| HIS | 168 | 36.3 | 49.1 (8.0) | 3.3 (0.6) | |||||
| Genetic Analysis of Idiopathic Thrombophilia (GAIT2) | EUR | 896 | 49.4 | 39.7 (21.4) | 3.5 (0.8) | Clauss | |||
| Helsinki Birth Cohort Study (HBCS) | EUR | 1 321 | 40.6 | 61.4 (2.9) | 3.3 (1.0) | Clauss | |||
| Lothian Birth Cohort 1921 (LBC1921) | EUR | 486 | 42.4 | 76.1 (0.6) | 3.6 (0.9) | Clauss | |||
| Lothian Birth Cohort 1936 (LBC1936) | EUR | 988 | 50.8 | 69.6 (0.8) | 3.3 (0.6) | Clauss | |||
| Ludwigshafen Risk and Cardiovascular Health (LURIC) | EUR | 2 731 | 70.0 | 62.7 (10.6) | 4.0 (1.1) | Clauss | |||
| Marseille Thrombosis Association (MARTHA) | EUR | 985 | 29.0 | 45.4 (14.9) | 3.4 (0.7) | Clauss | |||
| Netherlands Epidemiology of Obesity (NEO) | EUR | 5 303 | 46.8 | 56.0 (6.0) | 3.0 (0.6) | Clauss | |||
| Netherlands Twin Registry (NTR) | EUR | 7 650 | 38.5 | 44.9 (14.6) | 2.8 (0.7) | Clauss | |||
| Precocious Coronary Artery Disease Study (PROCARDIS) | Cases | EUR | 4 196 | 73.0 | 62.2 (7.0) | 4.2 (1.0) | Clauss and IN | ||
| Controls | EUR | 2 224 | 76.2 | 55.1 (8.3) | 3.5 (0.9) | ||||
| Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) | EUR | 4 951 | 48.1 | 75.3 (3.3) | 3.6 (0.7) | Clauss | |||
| RETROVE | Cases | EUR | 398 | 49.2 | 61.8 (18.6) | 3.8 (0.9) | Clauss | ||
| Controls | EUR | 398 | 48.7 | 47.1 (18.2) | 3.4 (0.7) | ||||
| SardiNIA | EUR | 5 931 | 35.9 | 43.6 (17.6) | 3.3 (0.7) | Clauss | |||
| Study of Health in Pomerania (SHIP) | SHIP-START | EUR | 3 571 | 47.5 | 47.5 (15.6) | 3.0 (0.7) | Clauss | ||
| SHIP-TREND-B1 | EUR | 909 | 42.9 | 49.1 (13.4) | 3.0 (0.7) | Clauss | |||
| SHIP-TREND-B2 | EUR | 1 505 | 49.0 | 49.5 (15.0) | 3.0 (0.8) | Clauss | |||
| TWINSUK | EUR | 2 037 | 4.7 | 49.1 (12.6) | 3.0 (0.8) | Clauss | |||
| Viking Health Study-Shetland (VIKING) | EUR | 2 086 | 40.1 | 49.9 (15.2) | 3.5 (0.8) | Clauss | |||
| Women’s Genome Health Study (WGHS) | EUR | 22 962 | 0.0 | 54.2 (7.1) | 3.6 (0.8) | ITA | |||
| HRC Imputation | GOYA | EUR | 1 431 | 100.0 | 45.6 (7.9) | 3.1 (0.8) | FPA | ||
| Inter99 | EUR | 649 | 61.8 | 49.5 (6.4) | 2.1 (1.5) | UI | |||
| Rotterdam Study (RS) | RS1 | EUR | 2 252 | 36.5 | 70.5 (8.9) | 2.8 (0.7) | Clauss | ||
| RS2 | EUR | 673 | 45.5 | 64.8 (8.0) | 3.9 (0.9) | ||||
AFR, African American; AI/AN, American Indian or Alaska Native; ASN, East Asian American; EUR, European or European American; FPA, functional photometric assay; HIS, Hispanic or Latino; HN, heat-nephelometry; IN, immune-nephelometric; ITA, immunoturbidimetric assay; NA, missing; UI, ultrasensitive immunoassay; WGS, whole-genome sequencing.